Collegium Pharmaceutical, Inc. Net Cash Provided by (Used in) Continuing Operations
Collegium Pharmaceutical, Inc. (COLL) reported Net Cash Provided by (Used in) Continuing Operations of -$45.61 million for the 9-month period ending 2017-09-30, per its 10-Q filed 2017-11-08.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:NetCashProvidedByUsedInContinuingOperations · last filed 2017-11-08
- Collegium Pharmaceutical, Inc. net cash provided by (used in) continuing operations for the quarter ending 2017-09-30 was -$3.60M.
- Collegium Pharmaceutical, Inc. net cash provided by (used in) continuing operations for the quarter ending 2017-06-30 was -$18.35M.
- Collegium Pharmaceutical, Inc. net cash provided by (used in) continuing operations for the quarter ending 2017-03-31 was -$23.67M, a 160.63% decline year-over-year.
- Collegium Pharmaceutical, Inc. net cash provided by (used in) continuing operations for the quarter ending 2016-12-31 was $62.20M.
- Collegium Pharmaceutical, Inc. net cash provided by (used in) continuing operations for fiscal 2016 was $57.53M, a 38.84% decline from fiscal 2015.
- Collegium Pharmaceutical, Inc. net cash provided by (used in) continuing operations for fiscal 2015 was $94.06M.
- Collegium Pharmaceutical, Inc. net cash provided by (used in) continuing operations for fiscal 2014 was -$5.92M.
- Collegium Pharmaceutical, Inc. net cash provided by (used in) continuing operations for fiscal 2013 was -$4.38M.
| Period end | Net Cash Provided by (Used in) Continuing Operations 3 month | Net Cash Provided by (Used in) Continuing Operations 6 month | Net Cash Provided by (Used in) Continuing Operations 9 month | Net Cash Provided by (Used in) Continuing Operations 12 month |
|---|---|---|---|---|
| 2017-09-30 | -$3.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | -$21.95M derived: sum of 2 quarters · filed 2017-11-08 | -$45.61M 10-Q · filed 2017-11-08 | $16.58M derived: sum of 4 quarters · filed 2017-11-08 |
| 2017-06-30 | -$18.35M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | -$42.02M 10-Q · filed 2017-08-09 | $20.18M derived: sum of 3 quarters · filed 2017-08-09 | $462.00K derived: sum of 4 quarters · filed 2017-11-08 |
| 2017-03-31 | -$23.67M 10-Q · filed 2017-05-10 | $38.53M derived: sum of 2 quarters · filed 2017-05-10 | $18.81M derived: sum of 3 quarters · filed 2017-11-08 | -$5.17M derived: sum of 4 quarters · filed 2017-11-08 |
| 2016-12-31 | $62.20M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-10 | $42.48M derived: sum of 2 quarters · filed 2017-11-08 | $18.50M derived: sum of 3 quarters · filed 2017-11-08 | $57.53M 10-K · filed 2017-03-10 |
| 2016-09-30 | -$19.72M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | -$43.70M derived: sum of 2 quarters · filed 2017-11-08 | -$4.67M 10-Q · filed 2017-11-08 | -$14.43M derived: sum of 4 quarters · filed 2017-11-08 |
| 2016-06-30 | -$23.98M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | $15.05M 10-Q · filed 2017-08-09 | $5.29M derived: sum of 3 quarters · filed 2017-08-09 | -$1.67M derived: sum of 4 quarters · filed 2017-08-09 |
| 2016-03-31 | $39.03M 10-Q · filed 2017-05-10 | $29.27M derived: sum of 2 quarters · filed 2017-05-10 | $22.32M derived: sum of 3 quarters · filed 2017-05-10 | $89.74M derived: sum of 4 quarters · filed 2017-05-10 |
| 2015-12-31 | -$9.76M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-10 | -$16.72M derived: sum of 2 quarters · filed 2017-03-10 | $50.71M derived: sum of 3 quarters · filed 2017-03-10 | $94.06M 10-K · filed 2017-03-10 |
| 2015-09-30 | -$6.95M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-10 | $60.47M derived: sum of 2 quarters · filed 2016-11-10 | $103.83M 10-Q · filed 2016-11-10 | $101.28M derived: sum of 4 quarters · filed 2017-03-10 |
| 2015-06-30 | $67.42M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-11 | $110.78M 10-Q · filed 2016-08-11 | $108.23M derived: sum of 3 quarters · filed 2017-03-10 | $109.82M derived: sum of 4 quarters · filed 2017-03-10 |
| 2015-03-31 | $43.35M 10-Q · filed 2016-05-11 | $40.81M derived: sum of 2 quarters · filed 2017-03-10 | $42.40M derived: sum of 3 quarters · filed 2017-03-10 | $40.18M derived: sum of 4 quarters · filed 2017-03-10 |
| 2014-12-31 | -$2.54M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-10 | -$959.00K derived: sum of 2 quarters · filed 2017-03-10 | -$3.18M derived: sum of 3 quarters · filed 2017-03-10 | -$5.92M 10-K · filed 2017-03-10 |
| 2014-09-30 | $1.58M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-12 | -$633.00K derived: sum of 2 quarters · filed 2015-11-12 | -$3.37M 10-Q · filed 2015-11-12 | |
| 2014-06-30 | -$2.22M derived: 10-Q 6 month − 10-Q/A 3 month · filed 2015-08-12 | -$4.96M 10-Q · filed 2015-08-12 | ||
| 2014-03-31 | -$2.74M 10-Q/A · filed 2015-07-17 | |||
| 2013-12-31 | -$4.38M 10-K · filed 2016-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |